CeGaT

We help oncologists and cancer patients find the best therapy option, offering market leading comprehensive genetic tumour profiling, fusion transcripts identification, MRD and cancer monitoring, recommendations on targeted therapies, as well as neoantigen sequencing for cancer vaccine development. We also test for hereditary rare diseases. Established in 2009 and 100% privately owned, we are Europe’s largest sequencing service provider, working with hospitals, clinics, and private patients world-wide, including NHS genomic facilities. To ensure our high-quality standards, we are accredited according to CAP/CLIA, DIN EN ISO 15189, DIN EN ISO/IEC 17025, and our services are IVDR compliant (IVDR 2017/746). Genetic Insights You Can Trust.